Want to see HK:2138 full AI Analyst Report?
2138 Stock Chart & Stats
HK$0.57
-HK$0.01(-1.61%)
At close: 4:00 PM EST
HK$0.57
-HK$0.01(-1.61%)
Day’s Range― - ―
52-Week RangeHK$0.34 - HK$0.96
Previous CloseN/A
Volume263.00K
Average Volume (3M)629.78K
Market Cap
HK$515.57M
Enterprise ValueHK$1.22B
Total Cash (Recent Filing)HK$988.66M
Total Debt (Recent Filing)HK$1.26B
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.72%
Share Statistics
EPS (TTM)-0.34
Shares Outstanding1,185,211,300
10 Day Avg. Volume673,306
30 Day Avg. Volume629,783
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.14
P/FCF Ratio0.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)HK$5.02B
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationPositive operating and free cash flow gives the group internal funding capacity despite accounting losses. This can support clinic operations and investment without relying solely on external capital, although the 11.6% YoY FCF decline limits comfort.
Diversified Healthcare ServicesExposure to multiple healthcare verticals can diversify demand and create cross-referral opportunities across screening, aesthetics and clinical care. A broader service platform may also increase customer lifetime value and reduce dependence on one offering.
Positive Underlying Operating EarningsPositive EBITDA and EBIT indicate that the operating platform still generates earnings before financing, tax and non-cash charges. This provides a base for recovery if revenue stabilizes and the company improves cost control and service mix.
Bears Say
Sustained Revenue ContractionTwo years of declining revenue indicate weakening demand, reduced service volumes or pressure on pricing and mix. Continued contraction can limit operating leverage, reduce the ability to absorb fixed clinic costs and make a durable return to profitability more difficult.
Persistent Losses And Margin VolatilitySustained net losses weaken retained capital and reduce earnings visibility. The sharp gross-margin change also raises concerns about mix, pricing, cost structure or accounting classification, making future profitability and cash conversion harder to forecast.
Rising Leverage And Declining EquityHigher leverage alongside a shrinking equity base reduces financial flexibility and increases sensitivity to weak earnings. If losses persist, debt obligations may constrain investment in the service network and raise refinancing or balance-sheet risk.
EC Healthcare News
2138 FAQ
What was EC Healthcare’s price range in the past 12 months?
EC Healthcare lowest stock price was HK$0.34 and its highest was HK$0.96 in the past 12 months.
What is EC Healthcare’s market cap?
EC Healthcare’s market cap is HK$515.57M.
When is EC Healthcare’s upcoming earnings report date?
EC Healthcare’s upcoming earnings report date is Nov 26, 2026 which is in 94 days.
How were EC Healthcare’s earnings last quarter?
EC Healthcare released its earnings results on Jun 29, 2026. The company reported -HK$0.331 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.331.
Is EC Healthcare overvalued?
According to Wall Street analysts EC Healthcare’s price is currently Overvalued.
Does EC Healthcare pay dividends?
EC Healthcare pays a Annually dividend of HK$0.01 which represents an annual dividend yield of 1.72%. See more information on EC Healthcare dividends here
What is EC Healthcare’s EPS estimate?
EC Healthcare’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EC Healthcare have?
EC Healthcare has 1,185,211,300 shares outstanding.
What happened to EC Healthcare’s price movement after its last earnings report?
EC Healthcare reported an EPS of -HK$0.331 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.219%.
Which hedge fund is a major shareholder of EC Healthcare?
Currently, no hedge funds are holding shares in HK:2138
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EC Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.48%
Trailing 12-Months
Company Description
EC Healthcare
EC Healthcare, an investment holding firm, delivers an extensive range of medical and healthcare services throughout Hong Kong, Macau, and mainland China. Its operations are structured into three primary divisions: Medical, Aesthetic Medical and Beauty and Wellness, and an 'Others' category. The company's diverse service offerings include quasi-medical treatments, beauty and wellness programs, medical imaging, surgical procedures, aesthetic medicine, dentistry, hair restoration, vaccinations, chiropractic care, psychological support, and orthopedic services. Beyond direct patient care, EC Healthcare also provides administrative and management support, laboratory diagnostics, various marketing and performance marketing solutions, and even travel agency services. Furthermore, it retails beauty and skincare products, manages healthcare machinery, engages in property investment, offers multi-channel networking, and extends its expertise to veterinary services. Its product and service portfolio is primarily marketed under proprietary brands such as PRODERMA LAB, Swissline, Suissebeaute, and re:HEALTH. Established in 2005 and headquartered in Mong Kok, Hong Kong, the company was formerly known as Union Medical Healthcare Limited before rebranding to EC Healthcare in April 2021.
Technical Analysis
Innovative Pharmaceutical Biotech
―
Natural Beauty Bio-Technology
―
Dingdang Health Technology Group Ltd.
―
Herbs Generation Group Holdings Limited Class H
―
Eternal Beauty Holdings Limited
―